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Replicated methylation changes associated
with eczema herpeticum and allergic
response
Meher Preethi Boorgula1†, Margaret A. Taub2†, Nicholas Rafaels1, Michelle Daya1, Monica Campbell1,
Sameer Chavan1, Aniket Shetty3, Chris Cheadle4, Sangjucta Barkataki5, Jinshui Fan6, Gloria David7, Terri H. Beaty2,
Ingo Ruczinski2, Jon Hanifin8, Lynda C. Schneider9, Richard L. Gallo10, Amy S. Paller11, Lisa A. Beck12,
Donald Y. Leung13, Rasika A. Mathias6† and Kathleen C. Barnes1,14*†
Abstract
Background: Although epigenetic mechanisms are important risk factors for allergic disease, few studies have evaluated
DNA methylation differences associated with atopic dermatitis (AD), and none has focused on AD with eczema
herpeticum (ADEH+). We will determine how methylation varies in AD individuals with/without EH and associated traits.
We modeled differences in genome-wide DNA methylation in whole blood cells from 90 ADEH+, 83 ADEH−, and 84
non-atopic, healthy control subjects, replicating in 36 ADEH+, 53 ADEH−, and 55 non-atopic healthy control subjects. We
adjusted for cell-type composition in our models and used genome-wide and candidate-gene approaches.
Results: We replicated one CpG which was significantly differentially methylated by severity, with suggestive
replication at four others showing differential methylation by phenotype or severity. Not adjusting for eosinophil
content, we identified 490 significantly differentially methylated CpGs (ADEH+ vs healthy controls, genome-wide). Many
of these associated with severity measures, especially eosinophil count (431/490 sites).
Conclusions: We identified a CpG in IL4 associated with serum tIgE levels, supporting a role for Th2 immune mediating
mechanisms in AD. Changes in eosinophil level, a measure of disease severity, are associated with methylation changes,
providing a potential mechanism for phenotypic changes in immune response-related traits.
Keywords: Atopic dermatitis, Eczema herpeticum, Human epigenetics, DNA methylation, Infinium Methylation 450K array,
Methylation EPIC array
Background
Atopic dermatitis (AD), a complex chronic skin disease,
affects up to 30% of children. It often persists into adult-
hood [1, 2]. A primary symptom of AD is incessant
pruritus [3] which typically has an intermittent course
with flares and remissions. Eczema herpeticum (EH) is a
rare but serious complication of AD. The primary
predisposing factor for EH is HSV-1 exposure (in 2005–
2010, 54% of persons in the USA aged 14–49 had HSV-
1 infection [4]). In spite of HSV-1 infection being the
primary environmental risk factor in the development of
EH, only a small subset (less than 3%) of patients with
AD have a history of EH (ADEH+). ADEH+ patients
typically represent the severe end of the disease
spectrum, with more severe skin disease. They have re-
duced interferon responses and are highly allergic with
increased serum tIgE levels and eosinophilia [5–9]. Yet,
the factors contributing to ADEH+ are unclear. To date,
there is considerable evidence for genetic determinants
associated with viral dissemination [10–12] and out-
comes associated specifically with risk of ADEH+ and
disease severity [6, 8, 9, 13–20].
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DNA methylation, an epigenetic mechanism by which
gene expression is regulated without alterations in nu-
cleotide sequence, has been shown to contribute to the
risk of complex diseases, notably autoimmune disorders
and diseases of inflammation [21–24]. Risk of AD has
been shown to be correlated with changes in genomic
DNA methylation patterns [25–27] in lesional versus
non-lesional AD skin [28]. However, no study has exam-
ined patterns of methylation specific to ADEH+. Com-
mon contributors to both ADEH− and ADEH+ are skin
barrier abnormalities and immune dysregulation while
risk factors for ADEH+ are early-onset and persistent se-
vere AD [5, 29]. In spite of these known risks, the patho-
physiology of ADEH+ still is not completely understood
[30]. In addition to identifying a methylation-specific sig-
nature for ADEH+, a goal of the current study was to
determine whether an easily accessible tissue such as
whole blood can be the source of a biomarker which
might facilitate the early diagnosis of patients with AD
prone to disseminated viral infections, and whether or
not methylation changes in the blood can distinguish be-
tween ADEH+ and ADEH−.
Using blood as a surrogate tissue to identify methyla-
tion changes associated with AD, and ADEH+ specific-
ally, raises the challenge of performing an analysis that
will control for signatures of immune response present
in the blood. To account for differences in eosinophils
across subjects, we estimated eosinophil fractions from
the methylation data and included these fractions, along
with those of other cell types composing each sample, in
linear models. We contend that the CpGs associated
with ADEH+ status and severity in this analysis should
be independent of the specific immune response
reflected by eosinophil levels.
However, similar to other recent reports focused on
asthma and IgE-mediated allergic disease [31, 32], we
found in further unadjusted analysis that the strongest
factor to influence methylation differences was eosino-
phil count. To explore this phenomenon in our data, we
also examined methylation differences without adjusting
for eosinophil fractions in discovery subjects and found
many sites that were different between ADEH+ and
healthy control individuals and which were related to
various disease severity measures. We present discovery
and replication results for all analyses and conclude with
a discussion of the challenges of interpreting results
from blood methylation analysis for an immune-related
disease like AD.
Results
Estimation of cell-type composition and assessment of
model calibration
Estimated cell fractions were included in all models to
ensure removal of confounding effects for either 7 or 6
cell types (neutrophils and eosinophils combined as
granulocytes). See Additional file 1 for further details on
models and plots to assess model calibration.
Differentially methylated position (DMP) analysis:
genome-wide dichotomous comparison
Differential methylation analysis was performed for all
pairwise comparisons of phenotype groups, adjusting for
seven cell types, including eosinophils, estimated from
the data: ADEH− against healthy controls, ADEH+
against healthy controls, and ADEH− against
ADEH+ (see Table 1 for clinical characteristics of sam-
ples included in analysis). One CpG (cg18593727)
showed genome-wide significantly differential methyla-
tion between the ADEH+ patients and the healthy con-
trol group in our discovery analysis and showed
suggestive replication (discovery FDR adjusted q-value
0.0426, replication nominal p value 0.0345, Fig. 1). This
CpG was annotated to the HCLS1 gene (Hematopoietic
Cell-Specific Lyn Substrate 1), a substrate of the antigen
receptor-coupled tyrosine kinase, which plays a role in
antigen receptor signaling for both clonal expansion and
deletion in lymphoid cells.
Differentially methylated position (DMP) analysis:
targeted gene dichotomous comparison
Two CpGs, one in IL4 (cg23943829) and one in IL13
(cg04303330), showed significant differential methylation
between ADEH+ and healthy controls in the discovery
analysis (FDR adjusted q-values of 0.03 and 0.04, re-
spectively) and suggestive significance, including similar
effect sizes in the same direction, in replication (nominal
p values of 0.051 and 0.094, respectively, Table 2, Fig. 2,
Additional file 2: Table S2).
DMP analysis: serum tIgE levels in IL4, IL13, and IL4R
To address a previous link between IL4, IL13, and
IL4R and serum tIgE levels [33–35], we performed a
severity analysis limited to the 26 CpGs in these
three regions. We found six CpGs in the discovery
analysis, one of which replicated after Bonferroni
correction for the 9 tests carried out in the replica-
tion analysis (cg26787239 in IL4, discovery FDR ad-
justed q-value 0.0042, replication p value 0.0045) and
one with suggestive replication (cg15329179 in IL13,
discovery FDR adjusted q-value 0.0042, replication p
value 0.016), both showing association between
serum tIgE and methylation levels (Table 3, Fig. 3,
Additional file 2: Table S3).
Differentially methylated position (DMP) analysis:
dichotomous comparisons with six cell types
Based on results from recent work investigating methy-
lation patterns in blood in atopy-related disease (e.g.,
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asthma, Arathimos et al. [31], Wei Chen et al. [32]), we
investigated differential methylation patterns without
adjusting for differences in eosinophil fraction between
subjects. Differential methylation analysis was performed
for all pairwise comparisons of phenotype groups,
adjusting for the six main cell types estimated from the
data: ADEH− against healthy controls, ADEH+ against
healthy controls, and ADEH− against ADEH+. Compar-
ing ADEH+ with healthy controls, 490 CpGs were differ-
entially methylated (FDR-adjusted q-value < 0.05) and
comparing ADEH− with Controls, six CpGs were differ-
entially methylated (FDR-adjusted q-value < 0.05) (Add-
itional file 3: Table S4), of which five were also in the
group of ADEH+ to healthy control DMPs. Interestingly,
there were no CpGs that were significantly different be-
tween the ADEH− and ADEH+ phenotype groups, al-
though mean methylation among ADEH− individuals at
CpGs with significant ADEH+ to healthy control differ-
ences was to a large extent intermediate (452 of 490
CpGs, 92.2%) between ADEH+ and healthy controls’
methylation (Additional file 1: Figure S5).
DMP analysis: severity measures with six cell types
To further investigate the trend whereby ADEH− indi-
viduals have methylation values intermediate to healthy
controls and ADEH+ individuals but show no statisti-
cally significant differences when compared to the
ADEH+ patients, we performed an analysis investigating
the relationship between different AD severity measures
and methylation at the 491 CpGs that were significant
(FDR adjusted q-values < 0.05) for at least one pairwise
comparison. Severity measures included serum tIgE
levels, eosinophil counts [36–38], EASI score, and Rajka-
Langeland score; analyses were performed within the
collective AD group (ADEH−, ADEH+; N = 173) for
each of these sub-phenotypes.
The strongest associations were observed for eosinophil
counts with 431 out of 491 sites showing significant associ-
ation (FDR-adjusted q-values < 0.05) between methylation
and eosinophil counts (Additional file 4: Tables S5–S8,
Additional file 1: Figure S6). A significant association was
observed for serum tIgE levels at 335 sites, for EASI scores
at 337 sites, and Rajka-Langeland scores at 276 sites.
Gene ontology analysis for results from analysis with six
cell types
Gene ontology (GO) analysis was performed on the 490
CpGs with significant association from the analysis adjust-
ing for six cell types comparing ADEH+ to healthy controls.
Two GO terms were enriched (FDR-adjusted q-value < 0.1)
in the ADEH+ versus healthy controls group. Both terms,
GO:0002761 and GO:0002573, are biological processes in-
volved in the regulation of myeloid leukocyte differentiation
(Additional file 5: Table S9).
Discussion
With adjustment for the full set of seven cell types
in the model, one CpG significant in the discovery
phase showed suggestive replicated association with
the ADEH+ phenotype compared to healthy controls
in a genome-wide test (Fig. 1). This CpG is located
1 kb upstream of the HCLS1 gene (Hematopoietic
Fig. 1 Methylation levels (% methylation) by group for cg18593727 for discovery (left) and replication (right) data sets.
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Cell-Specific Lyn Substrate 1), encoding a substrate
of the antigen receptor-coupled tyrosine kinase,
which plays a role in antigen receptor signaling for
both clonal expansion and deletion in lymphoid
cells. One of its related pathways includes the Im-
mune response FcεRI pathway and FcεRI-mediated
dendritic cell signaling and antigen presentation,
which promotes the development and activation of
Th2 cells and contributes to allergic inflammatory
diseases [39], suggesting a potential role in allergic
disease.
Given extensive prior work conducted on the genetics
of AD, we focused our attention on a specific subset of
candidate genes for AD. Using a set of 129 CpGs that
belong to AD candidate genes of interest (FLG [5, 17,
18, 25, 29, 40], LCE1B [40, 41], RPTN [41, 42], IL4, IL13
[18, 30, 33–35, 40] and its receptors, IFNs [6, 7, 10] and
TSLP [13, 14, 18, 30, 40], see Additional file 1 Table
Fig. 2 Box plots showing distribution of methylation levels (% methylation) by phenotype group for cg04303330 (top row) and cg23943829
(bottom row) for discovery (left) and replication (right).
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S10), we identified CpGs significant by phenotype in the
discovery and suggestive in the replication data sets in
the IL13 and IL4 genes (Fig. 2, Table 2). This suggests
there is a significant association between methylation
and phenotype in these genes, even when taking differ-
ences in eosinophils into account. We also found repli-
cated association between methylation and serum tIgE
levels for a CpG in the IL4 gene region and suggestive
replication for a CpG in the IL13 gene region (Fig. 3,
Table 3). The CpG in the IL4 gene region, cg26787239,
which was significantly associated with serum tIgE levels,
was also the most significant signal in recent work per-
formed in an asthma cohort [43].
Reviewing published work examining the association
between changes in epigenetics and AD, we found no
prior study that accounted for differences in eosinophil
Fig. 3 Scatter plots showing correlation between methylation levels (% methylation, Beta) and log serum tIgE levels for cg26787239 (top row)
and cg15329179 (bottom row) for discovery (left) and replication (right).
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levels, so we used our 491 methylation changes associ-
ated with phenotype without adjusting for eosinophils
for comparison. Compared to Everson et al. [44], which
focused on both case-control differences in AD and a
comparison of individuals with low or high IgE levels, 11
of our CpGs overlapped with the top 22 CpGs signifi-
cantly different between individuals with AD compared
to controls [44]. However, we found no overlap with the
top 140 CpGs presented in [45], which were the result
of a related study that used random forests to compare
individuals with and without eczema. Reasons for this
lack of overlap include methodological differences and
differences in the phenotype being considered.
In addition to AD status, we also considered measures
of AD severity, specifically serum tIgE levels, which has
previously been associated with AD severity [36–38].
The selection of the IL4, IL13, and IL4R regions for in-
vestigation of serum tIgE levels was in fact based on
prior work showing that suppression of these Th2 cyto-
kines decreases serum tIgE levels [34], that these genes
are involved in the pathway influencing cytokine- and
receptor-mediated regulation of IgE [35], and that they
are implicated in genetic association studies examining
serum tIgE levels as an outcome [33]. In addition, gen-
etic loci near IL13 were shown to be methyl-QTLs for
CpGs in the promoter of IL13 indicating that methyla-
tion could play a functional role, linking genetics to out-
come [46]. In this context, our results linking methylation
near IL13 and IL4 to serum tIgE levels implicate a role for
methylation in determining the presence of serum tIgE or
vice versa.
Recent work has shown that a major contributor to
observed differences in methylation from whole blood
between groups with different allergic disease pheno-
types is a cross-sample variation in cell type compos-
ition, in particular, the eosinophil fraction [24, 31, 32].
Specific to AD, prior work has shown that the peripheral
eosinophil counts or serum levels of eosinophil-derived
proteins are a measure of disease severity [36–38]. To
explore this, we modeled the outcome between
Table 1 Clinical characteristics table for samples analyzed in discovery and replication data sets
Table 2 Summary statistics from discovery and replication from gene-based analysis comparing ADEH+ individuals to non-atopic
healthy controls, adjusted for Eos and Neu fractions. Both significant CpGs from the discovery stage were suggestive for replication
(based on a Bonferroni correction for 9 tests)
Discovery data set Replication data set
ID CHR POS
(hg19)
GENE Diff_EHNA Pval_EHNA qval_EHNA Diff_EHNA Pval_EHNA
cg23943829 5 132009111 IL4 − 0.1425 0.0002 0.0287 − 0.0996 0.0509
cg04303330 5 131992430 IL13 − 0.1516 0.0007 0.044 − 0.1226 0.0941
Diff_EHNA difference in methylation values (M-value scale) between ADEH+ and healthy control group, Pval_EHNA p value obtained from ADEH+ vs healthy
control differential methylation analysis, qval_EHNA FDR corrected q values calculated on a set of CpGs in our genes of interest
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methylation and phenotype without adjusting for the es-
timated fraction of eosinophils in each sample to deter-
mine whether differences in eosinophil fractions might
contribute directly to differences in methylation that
then affect the outcome of interest. This analysis with
adjustment for six default cell types (eosinophils and
neutrophils combined as granulocytes) identifies bio-
logically relevant signals strongly associated with differ-
ent diseases from previous studies [40, 47]. The two
gene ontology (GO) terms associated with these 490
CpGs were both biological processes involved in the
regulation of myeloid leukocyte differentiation. While
we were not able to find specific links between myeloid
leukocyte differentiation and AD, we identified at least
one reference discussing the role of myeloid dendritic
cells in AD [48]. Interestingly, from the severity analyses
targeting serum tIgE levels, eosinophil counts, EASI
score and Rajka-Langeland scores, eosinophil counts
showed the largest number of CpGs that correlated with
methylation levels. Given the strong evidence that
ADEH+ patients have higher serum tIgE levels and cir-
culating eosinophil counts compared to ADEH− patients
[5, 36–38], it is of interest that we found methylation
changes associated with both of these phenotypes.
Other phenotypes related to allergic response, such as
asthma, face similar challenges with cell composition
confounding. In fact, methylation analysis recently per-
formed in asthma patients identified CpGs strongly asso-
ciated with asthma that were also significant in our
analyses, in both cases without adjustment for eosinophil
fractions. Specifically, cg10159529 (IL5RA) and
cg27469152 in the 3′UTR region of the EPX gene were
highly significant in the asthma analysis [31] and in our
comparisons of ADEH+ patients versus healthy controls
(FDR-adjusted q-value < 0.05) when not adjusting for eo-
sinophils. These genes have known links to both eosino-
phil functions and allergic sensitization. DNA
methylation in CpGs annotated to the ZFPM1
(cg04983687, cg08940169) and ACOT7 (cg09249800,
cg21220721, cg11699125) genes were also shown to be
strongly associated in the asthma study and in our ana-
lysis focusing on ADEH+. However, as in our AD study,
if eosinophil fractions were adjusted for in the asthma
analysis, residual differential methylation comparing
asthma cases to controls was nearly absent. While there
is strong confounding between differences in eosinophil
count, differences in methylation and AD status, these
changes in methylation could lead to functional differ-
ences that are a consequence of this change in cellular
composition.
Conclusions
In summary, we find replication for one CpG associated
with serum tIgE in the IL4 gene and suggestive replica-
tion for four CpGs associated with EH compared to
healthy controls or with AD severity measures, three of
which fall in two genes of interest, IL13 and IL4. As pre-
vious gene expression studies have identified higher ex-
pression of IL4 and IL13 in a specific disease group and
have led to a treatment using a monoclonal antibody
(dupilumab) to block these molecules [34], our hope is
that a similar treatment could arise from the results of
this study, in conjunction with further work on the epi-
genetics of eczema herpeticum. We also show that eo-
sinophil level plays a significant role in methylation
patterns in individuals with AD, presenting both a po-
tential confounder and a potential mechanism for enact-
ing methylation changes that could lead to phenotypic
changes.
Methods
Study Subjects
Discovery
ADEH+ subjects were defined as patients with AD who
had at least one previous EH episode as physician docu-
mented in Beck et al. [5]. ADEH− subjects were defined
Table 3 Summary statistics from discovery and replication from gene-based analysis for serum tIgE levels, not adjusted for Eos and
Neu fractions. One significant CpG from the discovery stage replicated (based on a Bonferroni correction for 9 tests) with an
additional CpG suggestive of replication
Discovery data set Replication data set
ID CHR POS
(hg19)
GENE Diff_IgE_cases Pval_IgE_cases qval_IgE_cases Diff_IgE_cases Pval_IgE_cases
cg26787239 5 132008525 IL4 − 0.1073 0.0002 0.0042 − 0.07098 0.0045
cg15329179 5 131993728 IL13 − 0.08296 0.00033 0.0042 − 0.0628 0.01595
cg06641959 16 27325254 IL4R 0.05223 0.00251 0.0163 − 0.0035 0.8569
cg06967316 5 131993853 IL13 − 0.04903 0.00192 0.0163 − 0.0096 0.6556
cg14523284 5 131993614 IL13 − 0.06025 0.00335 0.0174 0.0049 0.7816
cg23943829 5 132009111 IL4 − 0.0549 0.0055 0.0237 − 0.0258 0.2095
Diff_IgE_cases difference in methylation values (M-value scale), Pval_IgE_cases p value obtained from differential methylation analysis for serum tIgE levels,
qval_IgE_cases FDR corrected q values calculated on set of CpGs in IL4 and IL13 genes
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as patients with AD with no history of EH. Non-atopic
subjects were defined as having no individual or family
history of atopy and average total IgE less than 100 kU/
L, as in [5]. Methylation studies were conducted on a
subset of participants including 100 ADEH+, 100 ADEH
−, and 100 non-atopic subjects (NA), see Additional file
1: Table S1.
Replication
In order to replicate our initial findings, methylation stud-
ies were conducted on 56 ADEH+, 56 ADEH−, and 56
non-atopic subjects (NA), see Additional file 1: Table S1.
Measurements of AD severity
All study participants underwent a detailed history,
physical examination, disease severity assessment, and
blood draw. For all AD patients, disease severity was
assessed by the Rajka-Langeland and the Eczema Area
and Severity Index (EASI) scoring systems. The total eo-
sinophil count (cells/mm3) was calculated from the
“CBC with differential” blood test. Log-transformed
values for IgE, Eosinophil count, EASI, and phadiatop
were used for the analysis. In order to adjust for any
values less than 1 in the data set, before applying a log10
transformation, we added 10 to all eosinophil counts
and 1 to all EASI and phadiatop values. A Box-Cox trans-
formation with a lambda of 1.5 was applied to the Rajka-
Langeland score in order to normalize the distribution.
Quality control and preprocessing
Sample preparation
Standard protocols for preparing DNA methylation
data using Illumina’s array technology were followed
for discovery and replication. See Additional file 1 for
further details.
Discovery data set
Methylation data was quality control tested using the
“minfi” R-package [49]. All analyses throughout, with
one exception below, were run using R version 3.3.1 and
minfi 1.18.6. A total of 39 samples (15 Controls, 15
ADEH− and 9 ADEH+ samples) were removed from
further analysis as a result of either low methylated/
unmethylated median values (Additional file 1: Figure
S1) (12 controls, 14 ADEH−, and 7 ADEH+ samples) or
due to gender mismatches (4 controls: 1 also failed QC,
1 ADEH−, and 2 ADEH+ samples) between the pheno-
type annotations and the calls generated by the minfi
getSex function (Additional file 1: Figure S2). Three sam-
ples (2 Controls and 1 ADEH+ sample) were excluded
from the study as they did not meet the requirement of
“Non-Hispanic” and were ineligible per the protocol re-
quirements. One of the three samples (Control) was also
a QC failure so there were 41 samples excluded. Samples
were run in seven batches and excluding 41 samples left
the last batch with just two samples (ADEH−). In order
to balance the samples within batches on their pheno-
type, these two samples were also excluded. After filter-
ing samples for quality control (see Additional file 1),
the remaining 257 samples (Table 1) were normalized
using the minfi stratified quantile option. Probes map-
ping either to the X or Y chromosomes or in close prox-
imity to SNPs (at the CpG site or in the single-base
extension site for the array probe) were removed, leaving
456,513 CpG probes for analysis.
Replication data set
Because the Methylation 450K array was discontinued
by Illumina between generation of the discovery data set
and the replication data set, the Methylation EPIC chip
with 866,836 probes was used for our replication sam-
ples. Of the CpGs interrogated by the Methylation 450K
array, 93% were also included on the EPIC 850K chip.
The CpGs moved forward to replication from our dis-
covery data set were among those included on the new
platform.
Methylation data was quality control tested using the
minfi R-package [49]. Of the 168 samples run, there was
one sample that failed the initial experimental QC. One
hundred and sixty-seven samples were run through the
QC pipeline. Including that sample, a total of 6 samples
(1 Control, 3 ADEH−, and 2 ADEH+ samples) were re-
moved from further analysis as a result of either tech-
nical issues while performing the assay or low
methylated/unmethylated median values (Additional file
1: Figure S1) (1 Control, 1 ADEH−, and 1 ADEH+ sam-
ples) or due to gender mismatches (2 ADEH−: 1 also
failed QC and 2 ADEH+ samples) between the pheno-
type annotations and the calls generated by the minfi
getSex function (Additional file 1: Figure S2). There were
19 samples that were inadvertently included in discovery
and replication data sets. These 18 samples (ADEH+)
were excluded (1 was a QC failure) from the analysis.
After filtering samples for quality control (see Additional
file 1), the remaining 144 samples (Table 1) were nor-
malized using the minfi stratified quantile option. Probes
mapping either to the X or Y chromosomes or in close
proximity to SNPs (at the CpG site or in the single-base
extension site for the array probe) were removed, leaving
817,465 CpG probes for analysis. See Additional file 1
for further details about QC.
Data analysis
The following will provide a brief overview of our data
analysis and modeling pipeline. Additional details are
available in Additional file 1.
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Cell type distribution
Significant heterogeneity among different cell types as
found in blood (either whole or in PBMC fractions) has
been conclusively demonstrated to confound differential
methylation studies [50]. To test and control for the pos-
sibility of apparent changes in methylation status that
may result from changes in cell-type composition across
group, we used the minfi R-package, which incorporates
the method of Jaffe and Irizarry [50] to predict blood cell
count distributions for up to seven cell types: CD4T,
CD8T, eosinophils, neutrophils, B-cells, natural killer
cells, and monocytes. Boxplots of estimated cell fractions
of each of seven cell types for individuals split by pheno-
type group are shown in Fig. 4. We included these seven
components in our initial models. In addition, a com-
bined granulocyte signal composed of eosinophil and
neutrophil components can be estimated, resulting in six
cell-type fractions. We used these six cell-type estimates
in later analyses.
Batch adjustment
The missMethyl package was developed specifically for
analysis of 450K and EPIC array data and offers an im-
plementation of RUV-inverse [51] called RUVm [52] as
a solution for removing batch effects and unknown, un-
wanted variation from the data. We used this method to
ensure we were appropriately adjusting for batch effects
in our linear models.
Detection of differentially methylated positions (DMPs)
In both the discovery and replication analyses, DMPs
were detected using standard linear modeling ap-
proaches with covariates age, sex and batch, and esti-
mates of either six or seven cell-type fractions, along
with batch effect factors (estimated by RUVm). More
specifically, our model was of the form:
DNAm M−valueð Þ  β0 þ β1ðPredictor of
interestÞ þ β2 Sexð Þ þ β3 Ageð Þ þ β4 CD8Tð Þ
þβ5 CD4Tð Þ þ β6 NKð Þ þ β7 Bcellð Þ
þβ8 monocytesð Þ þ β9 eosinophilsð Þ þ β10
neutrophilsð Þ þ
XL
l¼1γlCl
where the term
PL
l¼1γ lCl includes factors estimated to
control for batch effects, and M-value refers to logit-
transformed percent methylation values.
P-value distribution adjustment was performed using
bacon [53] and then FDR-adjusted q-values were esti-
mated. In all cases, an FDR cutoff of 0.05 was used to
declare significance in discovery; for the 9 results carried
forward to replication, a Bonferroni adjustment was
used, giving a p value cutoff of 0.0056. For further details
of modeling choices, please see Additional file 1. The
following analyses were carried out:
1. Genome-wide tests of differential methylation by
group (ADEH+ vs healthy control, ADEH− vs
Fig. 4 Box plots for all cell composition estimates for clean samples by phenotype groups for seven cell types for the discovery data set (top
row) and the replication data set (bottom row).
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healthy control, ADEH+ vs ADEH−) adjusting for 7
cell types.
2. Gene-based tests of differential methylation by
group (ADEH+ vs healthy control, ADEH− vs
healthy control, ADEH+ vs ADEH−), adjusting for
7 cell types. A set of 129 CpGs that mapped to a
set of genes previously shown to be of interest in
EH, specifically FLG, LCE1B, RPTN, IL4, IL13 and
its receptors, IFNs, and TSLP was considered.
3. Genome-wide tests of differential methylation by
group (ADEH+ vs healthy control, ADEH− vs
healthy control, ADEH+ vs ADEH−) adjusting for 6
cell types (granulocytes instead of eosinophils and
neutrophils). For all CpGs significant from this
analysis, further modeling was performed using the
discovery data to assess the association between
severity measures (eosinophil counts, total serum
IgE (tIgE) levels, EASI score, and Rajka-Langeland
score) and methylation. Results from this analysis
were declared significant if q < 0.05. No results from
this analysis were carried forward for replication.
4. Gene-based tests of differential methylation by
serum tIgE level, adjusting for 6 cell types
(granulocytes instead of eosinophils and
neutrophils). A set of 26 CpGs in the IL4, IL13, and
IL4R genes was considered to test a specific
hypothesis of the role of these genes on serum tIgE.
Gene ontology (GO) enrichment analysis
Gene ontology enrichment analysis was performed with the
gometh function in missMethyl, which is designed specific-
ally to address potential biases in measuring gene-set en-
richment with the 450K methylation array [54].
Additional files
Additional file 1: Supplementary text. Figure S1. QC plot of methylated
to unmethylated median intensities for discovery and replication data
sets. Figure S2. Plot of chrX vs chrY median intensities to identify gender
mismatches for discovery and replication data sets. Figure S3. QQ plots
of p values (three phenotype comparisons) from models with seven cell
types (top) and six cell types (bottom) prior and post bacon adjustment.
Figure S4. QQ plots of p values (severity analysis) from models with
seven cell types (top) and six cell types (bottom) prior and post bacon
adjustment. Figure S5. Box plots for top 27 CpGs significant in ADEH+ vs
controls analysis. Figure S6. Scatter plots of top 27 CpGs significant in
eosinophil-methylation analysis showing eosinophil levels against
methylation values. Table S1. Clinical Characteristics table for all samples
in discovery and replication data sets. Table S10. References to support
the selection of genes for our gene-based analysis. (DOCX 4040 kb)
Additional file 2: Table S2 and S3. DMPs significant from gene-based
analysis for both phenotype groups and severity scores. (XLSX 31 kb)
Additional file 3: Table S4. DMPs significant from ADEH− vs controls
and/or ADEH+ vs controls analysis at an FDR threshold of 0.05 from
model adjusting for six cell types. (XLSX 91 kb)
Additional file 4: Tables S5–S8. DMPs significant from severity analysis
to follow up on results in Additional file 3: Table S4. (XLSX 120 kb)
Additional file 5: Table S9. Gene ontology (GO) analysis results for
ADEH+ vs healthy controls. (XLSX 11 kb)
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